| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000015223 |
| Receipt No. | R000017697 |
| Official scientific title of the study | The effect of lanthanum carbonate on hyperphosphatemia in chronic kidney disease patients not on dialysis. |
| Date of disclosure of the study information | 2014/10/01 |
| Last modified on | 2016/09/25 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | The effect of lanthanum carbonate on hyperphosphatemia in chronic kidney disease patients not on dialysis. | |
| Title of the study (Brief title) | ELAC-Hyper-CKD (Effect of LAnthanum Carbonate on Hyperphosphatemia in Chronic Kidney Disease patients) | |
| Region |
|
|
| Condition | ||
| Condition | non-dialysis chronic kidney disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To compare the effect of lanthanum carbonate and/or existing treatment on FGF23 level in chronic kidney disease (CKD) patients not on dialysis. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Change from baseline and compare between 2 groups, as follow items :
FGF23, alfa-Klotho and sclerostin (at 2 months) |
| Key secondary outcomes | Change from baseline and compare between 2 groups, as follows:
Phosphate, Calcium, Phosphate excretion in urine, iPTH, wPTH (at 2 months) delta-FGF23, eGFR, 1/Cr, Cr, iPTH, wPTH, BAP, TRACP-5b, OPG, Mg (at 12 months) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | Institution is considered as a block. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Lanthanum carbonate | |
| Interventions/Control_2 | Existing treatment for chronic kidney disease | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The patients of filling the following all criteria and having ability for agreement
1) Chronic kidney disease stage G3-G4 (15 mL/min/1.73m2<=GFR<60 mL/min/1.73m2) 2) Hyperphosphatemia patients without receiving phosphate binder treatment (serum phosphate>4.5 mg/dL) 3) Available for follow-up for at least 1 year in the opinion of the investigator |
|||
| Key exclusion criteria | 1)<20years old
2)Malignancy of any type 3)Contraindications to lanthanum carbonate 4)Diabetes mellitus 5)Renal transplant 6)Pregnant or breast-feeding women 7)Ineligible patients for this study according to the investigator's judgment |
|||
| Target sample size | 140 | |||
| Research contact person | |
| Name of lead principal investigator | Takashi Shigematsu |
| Organization | Wakayama Medical University |
| Division name | Division of Nephrology |
| Address | 811-1, Kimiidera Wakayama city, Wakayama |
| TEL | +81-73-441-0638 |
| taki@wakatyama-med.ac.jp | |
| Public contact | |
| Name of contact person | Masaki Ohya |
| Organization | Wakayama Medical University |
| Division name | Division of Nephrology |
| Address | 811-1, Kimiidera Wakayama city, Wakayama |
| TEL | +81-441-0639 |
| Homepage URL | |
| m-ohya@wakayama-med.ac.jp | |
| Sponsor | |
| Institute | Wakayama Medical University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Bayer Yakuhin, Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 和歌山県立医科大学(和歌山県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000017697 |